ATE360441T1 - Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen - Google Patents

Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen

Info

Publication number: ATE360441T1
Authority: AT; Austria
Prior art keywords: bind; formation; inhibiting; inhibitors; complement inhibitors
Prior art date: 2001-08-17

Application number

AT02768574T

Other languages

English (en)

Inventor

Michael S C Fung

Cecily Sun

Meisheng Lu

William Sun

Original Assignee

Tanox Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-17

Filing date

2002-08-17

Publication date

2007-05-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=23214536&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE360441(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2002-08-17 Application filed by Tanox Inc filed Critical Tanox Inc

2007-05-15 Application granted granted Critical

2007-05-15 Publication of ATE360441T1 publication Critical patent/ATE360441T1/de

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
General Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Molecular Biology (AREA)
Urology & Nephrology (AREA)
Biomedical Technology (AREA)
Hematology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Microbiology (AREA)
Cell Biology (AREA)
Physics & Mathematics (AREA)
Pathology (AREA)
General Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
Food Science & Technology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Biotechnology (AREA)
Endocrinology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Heart & Thoracic Surgery (AREA)
Pulmonology (AREA)
Dermatology (AREA)
Rheumatology (AREA)
Vascular Medicine (AREA)

AT02768574T 2001-08-17 2002-08-17 Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen ATE360441T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US31313701P	2001-08-17	2001-08-17

Publications (1)

Publication Number	Publication Date
ATE360441T1 true ATE360441T1 (de)	2007-05-15

Family

ID=23214536

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT02768574T ATE360441T1 (de)	2001-08-17	2002-08-17	Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen

Country Status (13)

Country	Link
US (6)	US7432356B2 (de)
EP (1)	EP1425042B2 (de)
JP (2)	JP4958387B2 (de)
CN (2)	CN100391537C (de)
AT (1)	ATE360441T1 (de)
AU (1)	AU2002331601B2 (de)
BR (1)	BRPI0211953B8 (de)
CA (1)	CA2457461C (de)
DE (1)	DE60219801T3 (de)
ES (1)	ES2283594T5 (de)
MX (2)	MXPA04001301A (de)
PT (1)	PT1425042E (de)
WO (1)	WO2003015819A1 (de)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2283594T5 (es) *	2001-08-17	2016-03-15	Genentech, Inc.	Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b
NZ540735A (en)	2002-12-02	2008-08-29	Resistentia Pharmaceuticals Ab	Methods and materials for treating inflammatory conditions using a polypeptide comprising a self-C5 amino acid segment and a non-self amino acid segment
CN1787741B (zh) *	2003-05-15	2011-08-17	唐纳士公司	用于预防和治疗败血症的方法与组合物
DK1755674T3 (en)	2004-05-14	2015-02-09	Alexion Pharma Inc	PROLONGED SURVIVAL OF A allograft by inhibiting complement activity
WO2006093053A1 (ja)	2005-03-02	2006-09-08	Astellas Pharma Inc.	ヒストンデアセチラーゼ阻害剤の新規ｐｄマーカー
RU2007147938A (ru) *	2005-06-14	2009-07-20	Цитос Биотехнологи Аг (Ch)	Конъюгаты антигенов и их применение
US20070292421A1 (en) *	2005-07-28	2007-12-20	Feinberg Bruce B	Method for treating preeclampsia
HUE026423T2 (en) *	2005-11-04	2016-05-30	Genentech Inc	Use of complement biosynthetic pathway inhibitors for treating eye diseases
CA2644020C (en)	2006-03-02	2016-05-10	Alexion Pharmaceuticals, Inc.	Prolongation of survival of an allograft by inhibiting complement activity
SI2359834T1 (sl)	2006-03-15	2017-02-28	Alexion Pharmaceuticals, Inc.	Zdravljenje pacientov,ki imajo paroksizmalno nočno hemoglobinurijo, z zaviralcem komplementa
IN2014DN10515A (de)	2006-03-31	2015-08-21	Chugai Pharmaceutical Co Ltd
CN101506237B (zh) *	2006-08-22	2014-05-07	G2炎症私人有限公司	具有改进性能的抗-C5aR抗体
US9388235B2 (en)	2006-09-05	2016-07-12	Alexion Pharmaceuticals, Inc.	Methods and compositions for the treatment of antibody mediated neuropathies
SI2097455T1 (sl) *	2006-11-02	2015-03-31	Genentech, Inc.	Humanizirana protitelesa proti faktorju tipa d
MX336725B (es)	2007-09-26	2016-01-28	Chugai Pharmaceutical Co Ltd	Metodo de modificacion del punto isoelectrico de anticuerpos medinate la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
TWI700293B (zh)	2008-04-11	2020-08-01	日商中外製藥股份有限公司	重複結合複數個抗原的抗體
CR20170001A (es)	2008-04-28	2017-08-10	Genentech Inc	Anticuerpos anti factor d humanizados
CN102264227B (zh)	2008-12-22	2014-07-23	凯莫森特里克斯股份有限公司	C5aR拮抗剂
EP2327725A1 (de) *	2009-11-26	2011-06-01	InflaRx GmbH	Anti-C5a-bindende Teile mit hoher Blockieraktivität
EA028899B1 (ru)	2010-04-30	2018-01-31	Алексион Фармасьютикалз, Инк.	АНТИ-C5a-АНТИТЕЛА И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ
RS56332B1 (sr)	2010-06-24	2017-12-29	Chemocentryx Inc	Antagonisti c5ar
KR102568454B1 (ko)	2010-11-30	2023-08-18	추가이 세이야쿠 가부시키가이샤	복수 분자의 항원에 반복해서 결합하는 항원 결합 분자
EP2468295A1 (de)	2010-12-21	2012-06-27	Affiris AG	Impfstoffe basierend auf Komplementprotein C5a Peptide
CN103596982B (zh)	2011-06-06	2016-11-02	诺沃—诺迪斯克有限公司	治疗性抗体
EP3511339B1 (de) *	2012-02-20	2025-04-09	IPC Research, LLC	An die menschliche komplementkomponente c5 bindende polypeptide
US9133269B2 (en)	2012-08-24	2015-09-15	Anaptysbio, Inc.	Humanized antibodies directed against complement protein C5
JP2016523829A (ja) *	2013-05-08	2016-08-12	ノヴォノルディスクアー／エス	Ｃ５ａｒアンタゴニストの使用
US20140335546A1 (en) *	2013-05-10	2014-11-13	G J Carroll Pty Ltd	Devices and Methods for Determining the Risk of Developing a Serious Infection
CA2920666A1 (en)	2013-08-12	2015-02-19	Genentech, Inc.	Compositions and method for treating complement-associated conditions
JP6767865B2 (ja)	2013-08-28	2020-10-14	スウェディッシュ・オーファン・バイオヴィトラム・アーベー（ペーウーベーエル）	ヒト補体ｃ５に結合する安定なポリペプチド
AU2014314214C1 (en)	2013-08-28	2019-01-24	Affibody Ab	Binding polypeptides having a mutated scaffold
NZ631007A (en) *	2014-03-07	2015-10-30	Alexion Pharma Inc	Anti-c5 antibodies having improved pharmacokinetics
KR20160127042A (ko) *	2014-03-20	2016-11-02	인플라알엑스 게엠베하	바이러스성 폐렴의 치료를 위한 c5a의 억제제
CR20160561A (es)	2014-05-01	2017-05-03	Genentech Inc	Variantes del anticuerpo anti-factor d y sus usos
MX387238B (es)	2014-09-29	2025-03-18	Chemocentryx Inc	Procesos e compuestos intermedios en la preparación de antagonistas de c5ar.
KR101838645B1 (ko)	2014-12-19	2018-03-14	추가이 세이야쿠 가부시키가이샤	항-c5 항체 및 그의 사용 방법
TWI656133B (zh)	2014-12-19	2019-04-11	日商中外製藥股份有限公司	抗肌抑素之抗體、含變異Ｆｃ區域之多胜肽及使用方法
JP2018511557A (ja)	2015-01-22	2018-04-26	中外製薬株式会社	２種以上の抗ｃ５抗体の組み合わせおよび使用方法
TW201718014A (zh)	2015-10-12	2017-06-01	諾華公司	C5抑制劑於移植相關微血管病之用途
US10407510B2 (en)	2015-10-30	2019-09-10	Genentech, Inc.	Anti-factor D antibodies and conjugates
US10654932B2 (en)	2015-10-30	2020-05-19	Genentech, Inc.	Anti-factor D antibody variant conjugates and uses thereof
KR102467124B1 (ko)	2015-12-18	2022-11-15	추가이 세이야쿠 가부시키가이샤	항-c5 항체 및 사용 방법
JP7339733B2 (ja)	2016-01-14	2023-09-06	ケモセントリックス，インコーポレイティド	Ｃ３腎症を処置する方法
KR102667023B1 (ko)	2016-06-14	2024-05-21	리제너론 파아마슈티컬스, 인크.	항-c5 항체 및 이의 용도
PE20240825A1 (es)	2016-06-17	2024-04-18	Chugai Pharmaceutical Co Ltd	Anticuerpos anti-c5 y metodos de uso
CN109689099B (zh)	2016-08-05	2023-02-28	中外制药株式会社	用于预防或治疗il-8相关疾病的组合物
PL3577135T3 (pl)	2017-01-31	2023-12-04	Chugai Seiyaku Kabushiki Kaisha	Kompozycja farmaceutyczna do stosowania do leczenia lub zapobiegania chorobom związanym z c5
JP7364221B2 (ja) *	2017-03-06	2023-10-18	ザトラスティーズオブザユニバーシティオブペンシルバニア	抗ｃ５抗体およびその使用
EP3600421A4 (de) *	2017-03-23	2021-01-06	The Trustees of The University of Pennsylvania	Anti-c5a-antikörper und verwendungen davon
AU2018374469B2 (en)	2017-11-29	2022-06-16	F. Hoffmann-La Roche Ag	Target interference suppressed anti-drug antibody assay
CN120571008A (zh)	2017-12-13	2025-09-02	瑞泽恩制药公司	抗c5抗体组合及其用途
US20190247560A1 (en)	2018-02-13	2019-08-15	Gambro Lundia Ab	Extracorporeal devices and methods of treating complement factor related diseases
CR20210103A (es)	2018-08-01	2021-03-22	Chugai Pharmaceutical Co Ltd	Composición farmacéutica para usarse en el tratamiento o prevención de una enfermedad relacionada con c5 y método para tratar o prevenir una enfermedad relacionada con c5
EP3846850A4 (de)	2018-09-06	2022-06-15	The Trustees of the University of Pennsylvania	Humanisierte anti-c5-antikörper und verwendungen davon
EP4003408A1 (de)	2019-07-31	2022-06-01	F. Hoffmann-La Roche AG	Dosierungs- und verabreichungsschema zur behandlung oder vorbeugung von c5-bedingten krankheiten durch verwendung des anti-c5-antikörpers crovalimab
WO2021019036A1 (en)	2019-07-31	2021-02-04	F. Hoffmann-La Roche Ag	Dosage and administration regimen for the treatment or prevention of c5-related diseases by the use of the anti-c5 antibody crovalimab
TW202208427A (zh)	2020-05-06	2022-03-01	德商因夫萊亞斯有限公司	人源化抗ｃ５ａ抗體
WO2021254926A1 (en)	2020-06-16	2021-12-23	F. Hoffmann-La Roche Ag	Method for determining the free antigen of an antibody in a sample
WO2022012606A1 (en) *	2020-07-15	2022-01-20	Biosion Inc.	Antibodies binding c5 and uses thereof
WO2023050233A1 (en) *	2021-09-29	2023-04-06	The Trustees Of The University Of Pennsylvania	Humanized anti-c5a antibodies and uses thereof
US12180274B2 (en)	2023-05-26	2024-12-31	Inflarx Gmbh	Treatment of pneumonia and ARDS with inhibitors of C5a and IL-6 activity

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4686100A (en)	1985-04-02	1987-08-11	The Board Of Trustees Of The Leland Stanford Junior University	Method for the treatment of adult respiratory distress syndrome
JP2703764B2 (ja) *	1986-04-28	1998-01-26	シータスオンコロジーコーポレイション	補体成分Ｃ５ａに対するモノクローナル抗体
US5260203A (en) *	1986-09-02	1993-11-09	Enzon, Inc.	Single polypeptide chain binding molecules
US5256766A (en) *	1991-02-19	1993-10-26	The Regents Of The University Of California	Recombinant thrombin receptor and related pharmaceuticals
DE69533921T2 (de) *	1994-03-23	2005-12-01	Alexion Pharmaceuticals, Inc., New Haven	Verfahren zur reduktion von fehlfunktionen des immunsystems und der hämostase während des extrakorporalen kreislaufs
US6074642A (en)	1994-05-02	2000-06-13	Alexion Pharmaceuticals, Inc.	Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5562904A (en)	1994-07-21	1996-10-08	Alexion Pharmaceuticals, Inc.	Retroviral transduction of cells using soluble complement inhibitors
EP0777474B1 (de) *	1994-09-23	2005-12-21	Alexion Pharmaceuticals, Inc.	Verfahren zur behandlung von entzündlichen gelenkerkrankungen
US5572904A (en) *	1995-01-05	1996-11-12	Minculescu; Mihai C.	Oscillation lever arm engine
US6673346B1 (en) *	1999-08-31	2004-01-06	The Regents Of The University Of Michigan	Compositions and methods for the treatment of sepsis
ES2283594T5 (es)	2001-08-17	2016-03-15	Genentech, Inc.	Inhibidores de la ruta del complemento que se unen a C5 y C5a sin impedir la formación de C5b

2002
- 2002-08-17 ES ES02768574.2T patent/ES2283594T5/es not_active Expired - Lifetime
- 2002-08-17 BR BRPI0211953-6 patent/BRPI0211953B8/pt not_active IP Right Cessation
- 2002-08-17 WO PCT/US2002/026074 patent/WO2003015819A1/en not_active Ceased
- 2002-08-17 DE DE60219801.1T patent/DE60219801T3/de not_active Expired - Lifetime
- 2002-08-17 EP EP02768574.2A patent/EP1425042B2/de not_active Expired - Lifetime
- 2002-08-17 MX MXPA04001301A patent/MXPA04001301A/es active IP Right Grant
- 2002-08-17 CN CNB028161025A patent/CN100391537C/zh not_active Expired - Fee Related
- 2002-08-17 AU AU2002331601A patent/AU2002331601B2/en not_active Ceased
- 2002-08-17 CA CA2457461A patent/CA2457461C/en not_active Expired - Fee Related
- 2002-08-17 CN CN200810091622.4A patent/CN101387646B/zh not_active Expired - Fee Related
- 2002-08-17 PT PT02768574T patent/PT1425042E/pt unknown
- 2002-08-17 US US10/222,464 patent/US7432356B2/en not_active Expired - Fee Related
- 2002-08-17 JP JP2003520777A patent/JP4958387B2/ja not_active Expired - Lifetime
- 2002-08-17 AT AT02768574T patent/ATE360441T1/de active
- 2002-08-17 MX MX2015001193A patent/MX342385B/es unknown
2008
- 2008-01-24 US US12/011,058 patent/US8206716B2/en not_active Expired - Fee Related
2010
- 2010-09-01 JP JP2010195807A patent/JP5752374B2/ja not_active Expired - Fee Related
2012
- 2012-05-29 US US13/482,328 patent/US8372404B2/en not_active Expired - Fee Related
2013
- 2013-02-05 US US13/759,687 patent/US8907072B2/en not_active Expired - Fee Related
2014
- 2014-11-24 US US14/551,705 patent/US20150086572A1/en not_active Abandoned
2016
- 2016-03-22 US US15/076,960 patent/US20160200805A1/en not_active Abandoned

Also Published As

Publication number	Publication date
JP5752374B2 (ja)	2015-07-22
MXPA04001301A (es)	2004-07-08
BR0211953A (pt)	2005-02-01
DE60219801T3 (de)	2016-06-16
EP1425042A1 (de)	2004-06-09
US20080118508A1 (en)	2008-05-22
US8206716B2 (en)	2012-06-26
US8907072B2 (en)	2014-12-09
MX342385B (es)	2016-09-27
US20130230522A1 (en)	2013-09-05
EP1425042A4 (de)	2004-09-29
JP2005508889A (ja)	2005-04-07
US8372404B2 (en)	2013-02-12
US7432356B2 (en)	2008-10-07
CN100391537C (zh)	2008-06-04
BRPI0211953B8 (pt)	2021-05-25
HK1071304A1 (zh)	2005-07-15
US20150086572A1 (en)	2015-03-26
US20160200805A1 (en)	2016-07-14
CA2457461C (en)	2013-12-24
CA2457461A1 (en)	2003-02-27
AU2002331601B2 (en)	2006-04-13
JP4958387B2 (ja)	2012-06-20
CN101387646A (zh)	2009-03-18
CN101387646B (zh)	2016-08-10
WO2003015819A1 (en)	2003-02-27
US20120301483A1 (en)	2012-11-29
EP1425042B2 (de)	2016-02-10
PT1425042E (pt)	2007-07-11
JP2011051987A (ja)	2011-03-17
ES2283594T3 (es)	2007-11-01
ES2283594T5 (es)	2016-03-15
CN1553813A (zh)	2004-12-08
BRPI0211953B1 (pt)	2019-05-28
DE60219801D1 (de)	2007-06-06
DE60219801T2 (de)	2008-01-17
US20030129187A1 (en)	2003-07-10
EP1425042B1 (de)	2007-04-25

Legal Events

Date

Code

Title

Description

2007-10-15

UEP

Publication of translation of european patent specification

Ref document number: 1425042

Country of ref document: EP

2010-09-15

EEIH

Change in the person of patent owner

Publication	Publication Date	Title
ATE360441T1 (de)	2007-05-15	Komplement-inhibitoren die an c5 und c5a binden ohne die bildung von c5b zu hemmen
CA3156451A1 (en)	2021-04-15	ANTIBODIES WITH SPECIFICITY FOR NECTIN-4 AND THEIR USES
WO2020132066A8 (en)	2020-07-30	Bispecific anti-cd28 x anti-cd22 antibodies and uses thereof
MX2023001726A (es)	2023-02-22	Anticuerpos anti-c5 y usos de los mismos.
MA31899B1 (fr)	2010-12-01	Anticorps monoclonaux qui se lient au hgm-csf et compositions medicales les comprenant
CY1120665T1 (el)	2019-12-11	Ανθρωποποιημενα αντισωματα anti-cxcr5, παραγωγα αυτων και χρησεις τους
MA46619B1 (fr)	2021-09-30	Anticorps anti-il-33 et leurs utilisations
DK1951759T3 (da)	2010-05-10	Anti-EGFR-antistoffer
ATE449791T1 (de)	2009-12-15	Inhibierung von c5 komplement-aktivierung für die behandlung und vorbeugung von xeno-transplantat oder akute vaskuläre abstossung
CY1111958T1 (el)	2015-11-04	Θεραπευτικη χρηση αντισωματων anti-csi
BRPI0407058A (pt)	2006-01-17	Métodos de profilaxia e de tratamento de uma doença, composição farmacêutica, e, uso de um fragmento
DE602004024572D1 (de)	2010-01-21	Zusammensetzungen, die sich als inhibitoren von proteinkinasen eignen
CY1116093T1 (el)	2017-02-08	Χρηση νιντεντανιμπης για την αγωγη της πνευμονικης ινωσεως
EP2100903A3 (de)	2010-01-20	Anti-idiotypische Antikörper, die die Hemmungsaktivität eines hemmenden Antikörpers neutralisieren, der auf die C1-Domäne des Faktors VIII ausgerichtet ist
CY1124762T1 (el)	2022-07-22	Αναστολεις πρωτεïνης δεσμευσης creb (cbp)
MA33051B1 (fr)	2012-02-01	Variants de liaison anti-albumine serique ameliores
MA39821B1 (fr)	2020-09-30	Molécules de liaison spécifiques de l'il-21 et leurs utilisations
CR20210324A (es)	2021-07-14	Anticuerpos anti-pmel 17 y conjugados de los mismos
MX2022002672A (es)	2022-06-16	Anticuerpo anti-vsig4 o fragmento de union a antigeno y usos del mismo.
DE69426767D1 (de)	2001-04-05	Anti idiotypische Antikörper gegen Gonococcen und diese verwendende Verfahren und Zusammensetzungen.
MX2020013894A (es)	2021-05-27	Anticuerpos anti-factor xii/xiia y usos de los mismos.
DE602007010459D1 (de)	2010-12-23	Verwendung von Verbindungen, die die EF-Tu-Nucleolin Wechselwirkung vehindern, zur Verhinderung oder Behandlung von Tularämie
EP1878441A3 (de)	2008-09-10	Komplement-Inhibitoren, die an C5 und C5a binden, ohne die Bildung von C5b zu hemmen
ATE361071T1 (de)	2007-05-15	Verwendung von irbesartan zur vorbeugung oder behandlung pulmonaler hypertonie
MX2022001411A (es)	2022-03-25	Metodos para tratar o prevenir canceres que implican la administracion de agentes receptores anti-ccr5.